title: Ovarian hydrobursitis in female camels (Camelus dromedarius): the role of Chlamydophila abortus and a trial for medical treatment.
abstract: The occurrence of Chlamydophila abortus in female camels affected with ovarian hydrobursitis and a trial for medical treatment were studied. A total of 111 cases were included in two experiments. In Experiment 1, sera from 51 affected cases were tested for C. abortus antibody using enzyme-linked immunosorbent assay (ELISA). In Experiment 2, 60 female camels affected with bilateral ovarian hydrobursitis were divided into treated and control groups (n = 30 each). Based on the bursal diameter, females of both groups were subdivided into those having small (< 5 cm), medium (5-7 cm) or large (> 7 cm) bursae. Treated group received 20 mg/kg body weight oxytetracycline intramuscular, 4% lotagen intrauterine, and 500 μg cloprostenol intramuscular. Controls did not receive any treatment. All females were observed for 90 days non-return rate (NRR) and calving rate (CR). Antibodies against C. abortus were observed in 44/51 (86.3%) of the affected females. The 90 days NRR of the treated and control groups were 13/30 (43.3%) and 0/30 (0.0%), respectively, (P = 0.001), while the CR were 10/30 (33.3%) and 0/30 (0.0%), respectively, (P = 0.01). Based on bursal size, the 90 days NRR were 11/15 (73.3%), 2/7 (28.6%) and 0/8 (0.0%) for treated females having small, medium and large bursa, while the CR were 9/15 (60%), 1/7 (14.3%), and 0/8 (0.0%), respectively, (P = 0.01). In conclusion, it seems that C. abortus may be responsible for the spreading of the ovarian hydrobursitis syndrome in dromedaries. Small sized bursa could be medically treated.
authors.affiliation: Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, Qassim University, 51452 Buraydah, Qassim, Saudi Arabia. ahmedali77@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Ali
authors.forename: F A
authors.initials: FA
authors.lastname: Al-Sobayil
authors.forename: K M
authors.initials: KM
authors.lastname: Hassanein
authors.forename: A
authors.initials: A
authors.lastname: Al-Hawas
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000097:blood; D002162:Camelus; D023501:Chlamydophila / Q000145:classification* / Q000276:immunology; D023521:Chlamydophila Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D003008:Cloprostenol / Q000627:therapeutic use; D003408:Cresols / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005557:Formaldehyde / Q000627:therapeutic use; D007247:Infertility, Female / Q000662:veterinary; D008186:Luteolytic Agents / Q000627:therapeutic use; D010049:Ovarian Diseases / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D010118:Oxytetracycline / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D003408:Cresols; D004338:Drug Combinations; D008186:Luteolytic Agents; D005557:Formaldehyde; D003008:Cloprostenol; C001716:formaldehyde, meta-cresolsulfonic acid drug combination; D010118:Oxytetracycline